

ELECTRONIC SUPPLEMENTARY MATERIALS

Reality of patient-reported symptoms in 200 patients with eosinophilic granulomatosis with polyangiitis: A cross-sectional survey (The KUNPU Study)

Koichi Amano¹, Keita Ono², Kazuya Sumi², Hitomi Uchimura², Hayato Oka², Naoyuki Makita², Masami Taniguchi³

¹ Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan.

² Medical Department, AstraZeneca K.K., Osaka, Japan.

³ Clinical Research Center for Allergy and Rheumatology, National Hospital Organization Sagamihara National Hospital, Sagamihara, Kanagawa, Japan.

Corresponding author

Professor Koichi Amano

Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, 1981 Kamoda, Kawagoe, Saitama 350-8550, Japan

Tel: +81-49-228-3400

E-mail: ko_amano@saitama-med.ac.jp

Content	Page
Table S1 Consent and general characteristics	3
Table S2 Severity of EGPA-related symptoms in the past month and at the time of the worst relapse in the past year	5
Table S3 Most severe symptom in the past month or at the time of the worst relapse in the past year	6
Table S4 Impact of EGPA symptoms within the past month on daily life problems	7
Table S5 Patient-reported impressions of EGPA treatment at the time of the survey	8
Table S6 Subgroup analysis of patient characteristics: demographics and general clinical characteristics	9
Table S7 Subgroup analysis of the patients' impressions of treatment at the time of the survey	10
Table S8 Subgroup analysis of the proportions of patients with EGPA-related symptoms in the past month	11
Fig. S1 Patient-reported impressions of EGPA treatment at the time of the survey according to the use and dose of OGC	12
Fig. S2 Improvements in EGPA treatments desired by patients according to the use and dose of OGC	13
Fig. S3 Prevalence and severity of EGPA-related symptoms (a), number of symptoms (b), and most painful symptoms (c) experienced by the patients at the time of the worst relapse in the past year	14
Fig. S4 Prevalence and severity of EGPA-related symptoms among patients with an intractable disease subsidy among 55 patients not using an anti-IL-5/R α biologic (a) and 116 patients using an anti-IL-5/R α biologic (b)	16
Fig. S5 Proportions of patients with EGPA-related symptoms in the past month according to the use and dose of OGC	17

Table S1 Consent and general characteristics

Question	Options
Do you consent to participate in this survey?	Yes, no
Enter your age	Value (years)
Select your sex	Male, female, no answer
How long has it been since you were diagnosed with asthma?	Value (years)
How long has it been since you were diagnosed with EGPA?	Value (years)
How long did it take from the onset of symptoms to the diagnosis?	<1 month, ≥1 month to <3 months, ≥3 months to <6 months, ≥6 months to <1 year, ≥1 year to <3 years, ≥3 years
How many medical institutions did you visit from the onset of the EGPA symptoms to the diagnosis of EGPA?	Value (number of institutions, possible range 1–10)
Select all diseases you are suffering from other than EGPA.	Select one or more of the following: diabetes mellitus, osteoporosis, depression/anxiety, myocardial infarction/stroke/heart failure, hypercholesterolemia, hypertension
Select all drugs prescribed by the doctor and that you continuously use for the treatment of EGPA now.	Select one or more of the following: methylprednisolone, prednisolone, dexamethasone, betamethasone, hydrocortisone, azathioprine, methotrexate, mycophenolate mofetil, tacrolimus, ciclosporine, intravenous immunoglobulin, anti-IL-5/Rα biologics (mepolizumab, benralizumab), other biologics (rituximab) ^a
If you selected no biologics: have you ever used a biologic for the treatment of EGPA?	Yes, no
If you selected no biologics: has your doctor explained biologics for the treatment of EGPA before?	Yes, no
If you select no biologics (never before) but your doctor has explained biologics: select the reason why you do not use biologics to treat EGPA now.	Select one or more of the following: insufficient explanation by the doctor; EGPA was improved (symptoms were improved or resolved); I used a biologic before but EGPA symptoms did not improve; I had concerns about its safety; they are expensive; I do not want to use injections
If you selected no biologics (never before) but your doctor has explained biologics: If the doctor recommended using a biologic to treat EGPA, what explanation would convince you to use a biologic?	Select one or more of the following: the injection will improve the symptoms; more detailed explanation of the injection; more detailed explanation of current status of EGPA; drawbacks of the current treatment (the disease will worsen with time, adverse drug reactions, etc.); more detailed explanation of cost; explanation from staff other than doctors (nurse, medical clerk, pharmacist, or call center)
Select the OGC you are currently using.	Select one or more of the following: methylprednisolone, prednisolone, dexamethasone, betamethasone, hydrocortisone, none ^a
How much (mg) do you take of the OGC you are currently using? (If you take two 5 mg tablets daily, enter the total amount as 10 mg)	Number (for each drug)
Do you use an inhaler to treat asthma now?	Yes, no
Have you been hospitalized for worsening of EGPA symptoms within the past 1 year?	Yes, no

Has the dose of your drug increased or a new drug prescribed for worsening of EGPA symptoms within the past 1 year?	Yes, no
Has your doctor previously explained the medical subsidy system for EGPA as an intractable disease subsidy?	Yes, no
Do you have a beneficiary certificate for intractable disease subsidy for EGPA?	Yes, no
How long did it take to be certified as having an intractable disease subsidy after diagnosis of EGPA?	<1 month, 1 month to <3 months, 3 months to <6 months, 6 months to <1 year, 1 year to <3 years, 3 years to <5 years, ≥5 years
Which is the main clinical department where you are treated for EGPA?	Rheumatology, Respiriology and Allergology, Neurology, Nephrology, other
Do you fully inform your doctor about your EGPA symptoms?	Absolutely yes, yes, uncertain, no, absolutely no

^a The responses included the generic and registered names for each drug

EGPA eosinophilic granulomatosis with polyangiitis, *IL* interleukin, *OGC* oral glucocorticoids, *Rα* receptor α

Table S2 Severity of EGPA-related symptoms in the past month and at the time of the worst relapse in the past year^a

Category		Explanation
Systemic	Fever/flu-like symptoms	Fever ($\geq 37.0^{\circ}\text{C}$) or flu-like symptoms with slight fever
	Muscle/grip strength	Disturbance due to reduced muscle strength or grip strength
	Joint/muscle pain	Joint/muscle pain
	Fatigue/malaise	Persisting fatigue or malaise
	Pain/numbness	Persisting tingling pain or numbness for a long time
Neurologic	Motor function	Limited motion with numbness in the hands and feet
Local/organ-related	Skin symptoms	Skin symptoms such as bruising, lump ulcers, and edema in the skin
	Renal symptoms	Urinary symptoms such as hematuria and proteinuria
	Gastrointestinal symptoms	Gastrointestinal symptoms, such as abdominal pain, diarrhea, or bloody stool
	Ocular symptoms	Eye symptoms such as visual disorder, double vision, and hyperemia
	Auditory symptoms	Ear symptoms, such as hearing loss, stuffed feeling in the ear, and ear pain
	Nasal/paranasal symptoms	Nasal symptoms such as disturbed smell, sticky nasal discharge, nasal bleeding, and nasal congestion
	Asthmatic symptoms	Asthmatic symptoms such as cough, sputum, shortness of breath, and stridor

^a The patients recalled the symptoms they experienced for two periods separately: (1) up to 1 month before the survey and (2) at the time of their worst relapse up to 1 year before the survey. All items were rated using a scale of 1 = none at all, 2 = a little, 3 = yes, 4 = very much
EGPA eosinophilic granulomatosis with polyangiitis

Table S3 Most severe symptom in the past month or at the time of the worst relapse in the past year^a

Select one symptom that had the greatest burden
1. Systemic symptoms: fever/flu-like symptoms
2. Systemic symptoms: muscle/grip strength
3. Systemic symptoms: joint/muscle pain
4. Systemic symptoms: fatigue/malaise
5. Neurological symptoms: pain/numbness
6. Neurological symptoms: motor function
7. Skin symptoms
8. Renal symptoms
9. Gastrointestinal symptoms
10. Eye symptoms
11. Ear symptoms
12. Nasal/paranasal symptoms
13. Asthmatic symptoms

^a The patients selected the symptom they felt had the greatest burden during two periods separately: (1) up to 1 month before the survey and (2) at the time of their worst relapse up to 1 year before the survey

Table S4 Impact of EGPA symptoms within the past month on daily life problems^a

Category		Description
Physical health	Daily life	Disturbance in daily physical activities (such as walking and going up stairs)
	Social life	Limited association with family and friends
	Work life	Limited work (study) or household chores
	Sleep	Sleep disturbance
	Acute change of condition	Schedules forced to change because of an acute change in condition
Mental health	Psychological anxiety	Psychological disturbance because of depressed mood or anxiety
	Emotions toward other people	Feeling of guilt toward other people because of concern about an acute change of the disease
	Apparently not ill	Distress about not being understood by other people because the disease is invisible
	Consultation	Distress because of difficulty discussing symptoms with anyone else

^a All items were rated using a scale of 1 = none at all, 2 = a little, 3 = yes, 4 = very much

EGPA eosinophilic granulomatosis with polyangiitis

Table S5 Patient-reported impressions of EGPA treatment at the time of the survey

Question	Possible responses
How well are you satisfied with the entire treatment for EGPA?	1. Very satisfied 2. Satisfied 3. Neither satisfied nor dissatisfied 4. Dissatisfied 5. Very dissatisfied
What improvements do you expect for the current treatments of EGPA?	Select one or more of the following: 1. Improvement of subjective symptoms 2. Reduction of side effects 3. Reduction of economic burden 4. Reduction of the number of drugs used 5. Reduction of the glucocorticoid dose 6. Control without glucocorticoids
<i>Impression of current EGPA treatment:</i>	
I think the treatment is good	1. I agree 2. I agree a little 3. I don't agree or disagree 4. I don't agree so much 5. I disagree
It's the latest treatment	1. I agree 2. I agree a little 3. I don't agree or disagree 4. I don't agree so much 5. I disagree
It's been highly effective	1. I agree 2. I agree a little 3. I don't agree or disagree 4. I don't agree so much 5. I disagree
My EGPA symptoms have improved	1. I agree 2. I agree a little 3. I don't agree or disagree 4. I don't agree so much 5. I disagree
Fewer adverse reactions	1. I agree 2. I agree a little 3. I don't agree or disagree 4. I don't agree so much 5. I disagree
I would like to continue it despite its cost	1. I agree 2. I agree a little 3. I don't agree or disagree 4. I don't agree so much 5. I disagree

Table S6 Subgroup analysis of patient characteristics: demographics and general clinical characteristics

		All patients	EGPA-intractable disease subsidy and use of biologics			Clinical department			Age		Use and dose of OGC		
			No intractable disease subsidy	With intractable disease subsidy, not using anti-IL-5/Rα biologics	With intractable disease subsidy and using an anti-IL-5/Rα biologic	Rheumatology	Respiratory /Allergy	Others (e.g. Neurology, Nephrology)	<65 years	≥65 years	No	≤4.0 mg/day	>4.0 mg/day
n		200	29	55	116	96	96	8	131	69	74	59	67
Age (years)	n	200	29	55	116	96	96	8	131	69	74	59	67
	Mean [SD]	57.9 [14.2]	52.9 [17.9]	56.7 [14.6]	59.8 [12.7]	58.5 [14.2]	57.1 [14.3]	61.1 [13.3]	50.2 [10.8]	72.6 [6.0]	58.0 [14.1]	58.2 [14.2]	57.6 [14.6]
	<65	131 (65.5%)	21 (72.4%)	38 (69.1%)	72 (62.1%)	61 (63.5%)	66 (68.8%)	4 (50.0%)	131 (100.0%)	0	48 (64.9%)	38 (64.4%)	45 (67.2%)
	≥65	69 (34.5%)	8 (27.6%)	17 (30.9%)	44 (37.9%)	35 (36.5%)	30 (31.3%)	4 (50.0%)	0	69 (100.0%)	26 (35.1%)	21 (35.6%)	22 (32.8%)
Sex	Male	77 (38.5%)	11 (37.9%)	20 (36.4%)	46 (39.7%)	36 (37.5%)	38 (39.6%)	3 (37.5%)	51 (38.9%)	26 (37.7%)	29 (39.2%)	20 (33.9%)	28 (41.8%)
	Female	122 (61.0%)	18 (62.1%)	34 (61.8%)	70 (60.3%)	59 (61.5%)	58 (60.4%)	5 (62.5%)	79 (60.3%)	43 (62.3%)	45 (60.8%)	39 (66.1%)	38 (56.7%)
	Prefer not to answer	1 (0.5%)	0	1 (1.8%)	0	1 (1.0%)	0	0	1 (0.8%)	0	0	0	1 (1.5%)
Number of healthcare facilities visited before EGPA diagnosis (limit 10 facilities)		Mean [SD]	2.5 [1.5]	2.3 [1.3]	2.7 [1.6]	2.7 [1.4]	2.4 [1.5]	1.9 [1.0]	2.7 [1.6]	2.1 [1.1]	2.6 [1.5]	2.6 [1.5]	2.4 [1.5]
Comorbidities*	Hypertension	45 (22.5%)	6 (20.7%)	13 (23.6%)	26 (22.4%)	23 (24.0%)	20 (20.8%)	2 (25.0%)	19 (14.5%)	26 (37.7%)	15 (20.3%)	14 (23.7%)	16 (23.9%)
	Osteoporosis	29 (14.5%)	5 (17.2%)	5 (9.1%)	19 (16.4%)	14 (14.6%)	12 (12.5%)	3 (37.5%)	11 (8.4%)	18 (26.1%)	8 (10.8%)	8 (13.6%)	13 (19.4%)
	Hyperlipidemia	18 (9.0%)	3 (10.3%)	7 (12.7%)	8 (6.9%)	4 (4.2%)	14 (14.6%)	0	11 (8.4%)	7 (10.1%)	4 (5.4%)	5 (8.5%)	9 (13.4%)
	Myocardial infarction, stroke, heart failure	17 (8.5%)	4 (13.8%)	5 (9.1%)	8 (6.9%)	8 (8.3%)	9 (9.4%)	0	10 (7.6%)	7 (10.1%)	8 (10.8%)	3 (5.1%)	6 (9.0%)
	Diabetes mellitus	11 (5.5%)	1 (3.4%)	4 (7.3%)	6 (5.2%)	2 (2.1%)	7 (7.3%)	2 (25.0%)	9 (6.9%)	2 (2.9%)	3 (4.1%)	3 (5.1%)	5 (7.5%)
	Depression/anxiety	11 (5.5%)	2 (6.9%)	6 (10.9%)	3 (2.6%)	2 (2.1%)	8 (8.3%)	1 (12.5%)	8 (6.1%)	3 (4.3%)	2 (2.7%)	4 (6.8%)	5 (7.5%)
	None of the above diseases have been diagnosed	108 (54.0%)	18 (62.1%)	24 (43.6%)	66 (56.9%)	55 (57.3%)	50 (52.1%)	3 (37.5%)	81 (61.8%)	27 (39.1%)	43 (58.1%)	31 (52.5%)	34 (50.7%)
Current medication for EGPA*	Prednisolone	118 (59.0%)	16 (55.2%)	39 (70.9%)	63 (54.3%)	55 (57.3%)	57 (59.4%)	6 (75.0%)	76 (58.0%)	42 (60.9%)	0	55 (93.2%)	63 (94.0%)
	Methylprednisolone	8 (4.0%)	3 (10.3%)	1 (1.8%)	4 (3.4%)	2 (2.1%)	5 (5.2%)	1 (12.5%)	5 (3.8%)	3 (4.3%)	0	3 (5.1%)	5 (7.5%)
	Betamethasone	5 (2.5%)	1 (3.4%)	2 (3.6%)	2 (1.7%)	1 (1.0%)	3 (3.1%)	1 (12.5%)	3 (2.3%)	2 (2.9%)	0	0	5 (7.5%)
	Dexamethasone	2 (1.0%)	0	0	2 (1.7%)	1 (1.0%)	0	1 (12.5%)	2 (1.5%)	0	0	0	2 (3.0%)
	Hydrocortisone	1 (0.5%)	1 (3.4%)	0	0	0	1 (1.0%)	0	1 (0.8%)	0	0	1 (1.7%)	0
	Anti-IL-5/Rα biologics	122 (61.0%)	6 (20.7%)	-	116 (100.0%)	59 (61.5%)	58 (60.4%)	5 (62.5%)	77 (58.8%)	45 (65.2%)	52 (70.3%)	34 (57.6%)	36 (53.7%)
	Azathioprine	20 (10.0%)	2 (6.9%)	6 (10.9%)	12 (10.3%)	12 (12.5%)	7 (7.3%)	1 (12.5%)	13 (9.9%)	7 (10.1%)	5 (6.8%)	5 (8.5%)	10 (14.9%)
	Methotrexate	7 (3.5%)	1 (3.4%)	2 (3.6%)	4 (3.4%)	7 (7.3%)	0	0	6 (4.6%)	1 (1.4%)	3 (4.1%)	1 (1.7%)	3 (4.5%)
	Intravenous immunoglobulin	7 (3.5%)	0	1 (1.8%)	6 (5.2%)	0	7 (7.3%)	0	6 (4.6%)	1 (1.4%)	1 (1.4%)	3 (5.1%)	3 (4.5%)
	Tacrolimus	5 (2.5%)	0	3 (5.5%)	2 (1.7%)	4 (4.2%)	1 (1.0%)	0	1 (0.8%)	4 (5.8%)	0	3 (5.1%)	2 (3.0%)
	Mycophenolate mofetil	3 (1.5%)	1 (3.4%)	0	2 (1.7%)	2 (2.1%)	1 (1.0%)	0	3 (2.3%)	0	1 (1.4%)	1 (1.7%)	1 (1.5%)
	Cyclophosphamide	3 (1.5%)	0	1 (1.8%)	2 (1.7%)	0	3 (3.1%)	0	2 (1.5%)	1 (1.4%)	0	1 (1.7%)	2 (3.0%)
	Ciclosporine	2 (1.0%)	1 (3.4%)	1 (1.8%)	0	2 (2.1%)	0	0	1 (0.8%)	1 (1.4%)	1 (1.4%)	0	1 (1.5%)
	Other biologics	4 (2.0%)	0	2 (3.6%)	2 (1.7%)	1 (1.0%)	3 (3.1%)	0	4 (3.1%)	0	1 (1.4%)	1 (1.7%)	2 (3.0%)
	Other agents	76 (38.0%)	8 (27.6%)	25 (45.5%)	43 (37.1%)	30 (31.3%)	43 (44.8%)	3 (37.5%)	50 (38.2%)	26 (37.7%)	32 (43.2%)	18 (30.5%)	26 (38.8%)
Glucocorticoid dose (mg/day) (prednisone equivalent) among patients using glucocorticoids (for patients taking multiple drugs, the total dose of each glucocorticoid is given)	n	126	19	40	67	57	62	7	83	43	-	59	67
	Mean [SD]	6.431 [8.775]	7.124 [7.777]	5.835 [5.363]	6.590 [10.581]	5.330 [3.863]	7.148 [10.905]	9.043 [15.201]	7.001 [10.182]	5.330 [4.985]	-	2.445 [0.963]	9.941 [10.877]
	≤4.0 mg/day	59 (46.8%)	9 (47.4%)	16 (40.0%)	34 (50.7%)	23 (40.4%)	33 (53.2%)	3 (42.9%)	38 (45.8%)	21 (48.8%)	-	59 (100.0%)	0
Hospitalization due to worsening of EGPA within the past year	>4.0 mg/day	67 (53.2%)	10 (52.6%)	24 (60.0%)	33 (49.3%)	34 (59.6%)	29 (46.8%)	4 (57.1%)	45 (54.2%)	22 (51.2%)	-	0	67 (100.0%)
	Yes	17 (8.5%)	4 (13.8%)	1 (1.8%)	12 (10.3%)	9 (9.4%)	7 (7.3%)	1 (12.5%)	13 (9.9%)	4 (5.8%)	3 (4.1%)	4 (6.8%)	10 (14.9%)
Increased dose/prescribed additional drug of treatment due to worsening EGPA within the past year	No	183 (91.5%)	25 (86.2%)	54 (98.2%)	104 (89.7%)	87 (90.6%)	89 (92.7%)	7 (87.5%)	118 (90.1%)	65 (94.2%)	71 (95.9%)	55 (93.2%)	57 (85.1%)
	Yes	45 (22.5%)	5 (17.2%)	12 (21.8%)	28 (24.1%)	22 (22.9%)	21 (21.9%)	2 (25.0%)	32 (24.4%)	13 (18.8%)	7 (9.5%)	9 (15.3%)	29 (43.3%)
	No	155 (77.5%)	24 (82.8%)	43 (78.2%)	88 (75.9%)	74 (77.1%)	75 (78.1%)	6 (75.0%)	99 (75.6%)	56 (81.2%)	67 (90.5%)	50 (84.7%)	38 (56.7%)

* Multiple responses were possible

EGPA eosinophilic granulomatosis with polyangiitis, IL interleukin, OGC oral glucocorticoids, Rα receptor α, SD standard deviation

Table S7 Subgroup analysis of the patients' impressions of treatment at the time of the survey

		All patients	EGPA-intractable disease subsidy and use of biologics			Clinical department			Age		Use and dose of OGC		
			No intractable disease subsidy	With intractable disease subsidy, not using anti-IL-5/Ra biologics	With intractable disease subsidy and using an anti-IL-5/Ra biologic	Rheumatology	Respiratory /Allergy	Others (e.g. Neurology, Nephrology)	<65 years	≥65 years	No	≤4.0 mg/day	>4.0 mg/day
n		200	29	55	116	96	96	8	131	69	74	59	67
How well are you satisfied with the entire treatment for EGPA?	Very satisfied	37 (18.5%)	5 (17.2%)	7 (12.7%)	25 (21.6%)	19 (19.8%)	17 (17.7%)	1 (12.5%)	27 (20.6%)	10 (14.5%)	18 (24.3%)	8 (13.6%)	11 (16.4%)
	Satisfied	116 (58.0%)	17 (58.6%)	32 (58.2%)	67 (57.8%)	58 (60.4%)	51 (53.1%)	7 (87.5%)	71 (54.2%)	45 (65.2%)	46 (62.2%)	37 (62.7%)	33 (49.3%)
	Neither satisfied nor dissatisfied	36 (18.0%)	5 (17.2%)	11 (20.0%)	20 (17.2%)	16 (16.7%)	20 (20.8%)	0	24 (18.3%)	12 (17.4%)	7 (9.5%)	13 (22.0%)	16 (23.9%)
	Not satisfied	8 (4.0%)	2 (6.9%)	3 (5.5%)	3 (2.6%)	3 (3.1%)	5 (5.2%)	0	6 (4.6%)	2 (2.9%)	3 (4.1%)	1 (1.7%)	4 (6.0%)
	Very dissatisfied	3 (1.5%)	0	2 (3.6%)	1 (0.9%)	0	3 (3.1%)	0	3 (2.3%)	0	0	0	3 (4.5%)
What improvements do you expect for the current treatments of EGPA? (multiple responses were possible)	Improvement of subjective symptoms	110 (55.0%)	13 (44.8%)	31 (56.4%)	66 (56.9%)	51 (53.1%)	55 (57.3%)	4 (50.0%)	76 (58.0%)	34 (49.3%)	40 (54.1%)	36 (61.0%)	34 (50.7%)
	Reduction of side effects	82 (41.0%)	11 (37.9%)	25 (45.5%)	46 (39.7%)	39 (40.6%)	40 (41.7%)	3 (37.5%)	58 (44.3%)	24 (34.8%)	17 (23.0%)	30 (50.8%)	35 (52.2%)
	Reduction of economic burden	92 (46.0%)	14 (48.3%)	23 (41.8%)	55 (47.4%)	42 (43.8%)	47 (49.0%)	3 (37.5%)	75 (57.3%)	17 (24.6%)	41 (55.4%)	26 (44.1%)	25 (37.3%)
	Reduction of the number of drugs used	73 (36.5%)	9 (31.0%)	18 (32.7%)	46 (39.7%)	36 (37.5%)	34 (35.4%)	3 (37.5%)	52 (39.7%)	21 (30.4%)	20 (27.0%)	23 (39.0%)	30 (44.8%)
	Reduction of the steroid dose	77 (38.5%)	11 (37.9%)	23 (41.8%)	43 (37.1%)	37 (38.5%)	35 (36.5%)	5 (62.5%)	51 (38.9%)	26 (37.7%)	7 (9.5%)	26 (44.1%)	44 (65.7%)
	Control without glucocorticoids	86 (43.0%)	12 (41.4%)	28 (50.9%)	46 (39.7%)	36 (37.5%)	44 (45.8%)	6 (75.0%)	60 (45.8%)	26 (37.7%)	13 (17.6%)	33 (55.9%)	40 (59.7%)
Impression of current EGPA treatment	I think the treatment is good	I disagree	2 (1.0%)	0	2 (1.7%)	1 (1.0%)	1 (1.0%)	0	2 (1.5%)	0	1 (1.4%)	1 (1.7%)	0
		I don't agree so much	8 (4.0%)	2 (6.9%)	4 (3.4%)	4 (4.2%)	4 (4.2%)	0	6 (4.6%)	2 (2.9%)	3 (4.1%)	2 (3.4%)	3 (4.5%)
		I don't agree or disagree	39 (19.5%)	12 (41.4%)	14 (25.5%)	12 (12.5%)	17 (17.7%)	1 (12.5%)	27 (20.6%)	12 (17.4%)	10 (13.5%)	10 (16.9%)	19 (28.4%)
		I agree a little	60 (30.0%)	6 (20.7%)	18 (32.7%)	30 (31.3%)	29 (30.2%)	1 (12.5%)	44 (33.6%)	16 (23.2%)	16 (21.6%)	20 (33.9%)	24 (35.8%)
		I agree	91 (45.5%)	9 (31.0%)	21 (38.2%)	40 (41.7%)	45 (46.9%)	6 (75.0%)	52 (39.7%)	39 (56.5%)	44 (59.5%)	26 (44.1%)	21 (31.3%)
	It's the latest treatment	I disagree	2 (1.0%)	0	2 (1.7%)	1 (1.0%)	1 (1.0%)	0	2 (1.5%)	0	1 (1.4%)	1 (1.7%)	0
		I don't agree so much	8 (4.0%)	3 (10.3%)	4 (7.3%)	6 (6.3%)	2 (2.1%)	0	5 (3.8%)	3 (4.3%)	3 (4.1%)	3 (5.1%)	2 (3.0%)
		I don't agree or disagree	43 (21.5%)	10 (34.5%)	16 (29.1%)	21 (21.9%)	21 (21.9%)	1 (12.5%)	31 (23.7%)	12 (17.4%)	10 (13.5%)	15 (25.4%)	18 (26.9%)
		I agree a little	62 (31.0%)	7 (24.1%)	19 (34.5%)	36 (37.5%)	24 (25.0%)	2 (25.0%)	38 (29.0%)	24 (34.8%)	25 (33.8%)	14 (23.7%)	23 (34.3%)
		I agree	85 (42.5%)	9 (31.0%)	16 (29.1%)	32 (33.3%)	48 (50.0%)	5 (62.5%)	55 (42.0%)	30 (43.5%)	35 (47.3%)	26 (44.1%)	24 (35.8%)
	It's been highly effective	I disagree	4 (2.0%)	0	2 (1.7%)	1 (1.0%)	3 (3.1%)	0	4 (3.1%)	0	1 (1.4%)	1 (1.7%)	2 (3.0%)
		I don't agree so much	12 (6.0%)	2 (6.9%)	8 (6.9%)	6 (6.3%)	6 (6.3%)	0	6 (4.6%)	6 (8.7%)	1 (1.4%)	4 (6.8%)	7 (10.4%)
		I don't agree or disagree	33 (16.5%)	9 (31.0%)	8 (14.5%)	18 (18.8%)	15 (15.6%)	0	22 (16.8%)	11 (15.9%)	9 (12.2%)	9 (15.3%)	15 (22.4%)
		I agree a little	64 (32.0%)	6 (20.7%)	28 (50.9%)	30 (31.3%)	30 (31.3%)	4 (50.0%)	45 (34.4%)	19 (27.5%)	22 (29.7%)	22 (37.3%)	20 (29.9%)
		I agree	87 (43.5%)	12 (41.4%)	15 (27.3%)	41 (42.7%)	42 (43.8%)	4 (50.0%)	54 (41.2%)	33 (47.8%)	41 (55.4%)	23 (39.0%)	23 (34.3%)
	My EGPA symptoms have improved	I disagree	5 (2.5%)	1 (3.4%)	3 (2.6%)	2 (2.1%)	3 (3.1%)	0	4 (3.1%)	1 (1.4%)	1 (1.4%)	4 (6.8%)	0
		I don't agree so much	14 (7.0%)	4 (13.8%)	5 (9.1%)	6 (6.3%)	7 (7.3%)	1 (12.5%)	7 (5.3%)	7 (10.1%)	0	5 (8.5%)	9 (13.4%)
		I don't agree or disagree	40 (20.0%)	8 (27.6%)	9 (16.4%)	19 (19.8%)	20 (20.8%)	1 (12.5%)	28 (21.4%)	12 (17.4%)	12 (16.2%)	11 (18.6%)	17 (25.4%)
		I agree a little	59 (29.5%)	4 (13.8%)	19 (34.5%)	33 (34.4%)	24 (25.0%)	2 (25.0%)	40 (30.5%)	19 (27.5%)	23 (31.1%)	19 (32.2%)	17 (25.4%)
		I agree	82 (41.0%)	12 (41.4%)	21 (38.2%)	36 (37.5%)	42 (43.8%)	4 (50.0%)	52 (39.7%)	30 (43.5%)	38 (51.4%)	20 (33.9%)	24 (35.8%)
	Fewer adverse reactions	I disagree	12 (6.0%)	1 (3.4%)	4 (7.3%)	5 (5.2%)	7 (7.3%)	0	10 (7.6%)	2 (2.9%)	1 (1.4%)	4 (6.8%)	7 (10.4%)
		I don't agree so much	28 (14.0%)	6 (20.7%)	11 (20.0%)	13 (13.5%)	13 (13.5%)	2 (25.0%)	21 (16.0%)	7 (10.1%)	4 (5.4%)	9 (15.3%)	15 (22.4%)
		I don't agree or disagree	48 (24.0%)	13 (44.8%)	11 (20.0%)	24 (24.0%)	24 (25.0%)	1 (12.5%)	34 (26.0%)	14 (20.3%)	10 (13.5%)	17 (28.8%)	21 (31.3%)
		I agree a little	40 (20.0%)	5 (17.2%)	11 (20.0%)	16 (16.7%)	23 (24.0%)	1 (12.5%)	26 (19.8%)	14 (20.3%)	16 (21.6%)	13 (22.0%)	11 (16.4%)
		I agree	72 (36.0%)	4 (13.8%)	18 (32.7%)	39 (40.6%)	29 (30.2%)	4 (50.0%)	40 (30.5%)	32 (46.4%)	43 (58.1%)	16 (27.1%)	13 (19.4%)
	I would like to continue it despite its cost	I disagree	8 (4.0%)	4 (13.8%)	0	4 (4.2%)	4 (4.2%)	0	5 (3.8%)	3 (4.3%)	3 (4.1%)	1 (1.7%)	4 (6.0%)
		I don't agree so much	9 (4.5%)	3 (10.3%)	3 (5.5%)	4 (4.2%)	4 (4.2%)	1 (12.5%)	8 (6.1%)	1 (1.4%)	3 (4.1%)	2 (3.4%)	4 (6.0%)
		I don't agree or disagree	40 (20.0%)	11 (37.9%)	13 (23.6%)	21 (21.9%)	18 (18.8%)	1 (12.5%)	33 (25.2%)	7 (10.1%)	17 (23.0%)	12 (20.3%)	11 (16.4%)
		I agree a little	47 (23.5%)	7 (24.1%)	13 (23.6%)	28 (29.2%)	18 (18.8%)	1 (12.5%)	26 (19.8%)	21 (30.4%)	14 (18.9%)	15 (25.4%)	18 (26.9%)
		I agree	96 (48.0%)	4 (13.8%)	26 (47.3%)	39 (40.6%)	52 (54.2%)	5 (62.5%)	59 (45.0%)	37 (53.6%)	37 (50.0%)	29 (49.2%)	30 (44.8%)

EGPA eosinophilic granulomatosis with polyangiitis, IL interleukin, OGC oral glucocorticoids, Ra receptor α

Table S8 Subgroup analysis of the proportions of patients with EGPA-related symptoms in the past month

			All patients	EGPA-intractable disease subsidy and use of biologics			Clinical department			Age		Use and dose of OGC		
				No intractable disease subsidy	With intractable disease subsidy, not using anti-IL-6/Rα biologics	With intractable disease subsidy and using an anti-IL-6/Rα biologic	Rheumatology	Respiratory /Allergology	Others (e.g. Neurology, Nephrology)	<65 years	≥65 years	No	≤4.0 mg/day	>4.0 mg/day
n			200	29	55	116	96	96	8	131	69	74	59	67
Systemic symptoms	Fever/flu-like symptoms	None at all	169 (84.5%)	23 (79.3%)	43 (78.2%)	103 (88.8%)	84 (87.5%)	80 (83.3%)	5 (62.5%)	105 (80.2%)	64 (92.8%)	61 (82.4%)	51 (86.4%)	57 (85.1%)
		A little	19 (9.5%)	4 (13.8%)	7 (12.7%)	8 (6.9%)	8 (8.3%)	9 (9.4%)	2 (25.0%)	17 (13.0%)	2 (2.9%)	10 (13.5%)	4 (6.8%)	5 (7.5%)
		Yes	8 (4.0%)	2 (6.9%)	3 (5.5%)	3 (2.6%)	3 (3.1%)	4 (4.2%)	1 (12.5%)	6 (4.6%)	2 (2.9%)	3 (4.1%)	4 (6.8%)	1 (1.5%)
		Absolutely yes	4 (2.0%)	0	2 (3.6%)	2 (1.7%)	1 (1.0%)	3 (3.1%)	0	3 (2.3%)	1 (1.4%)	0	0	4 (6.0%)
		Symptoms present*	31 (15.5%)	6 (20.7%)	12 (21.8%)	13 (11.2%)	12 (12.5%)	16 (16.7%)	3 (37.5%)	26 (19.8%)	5 (7.2%)	13 (17.6%)	8 (13.6%)	10 (14.9%)
	Muscle/grip strength	None at all	100 (50.0%)	14 (48.3%)	31 (56.4%)	55 (47.4%)	51 (53.1%)	46 (47.9%)	3 (37.5%)	67 (51.1%)	33 (47.8%)	45 (60.8%)	26 (44.1%)	29 (43.3%)
		A little	57 (28.5%)	9 (31.0%)	16 (29.1%)	32 (27.6%)	25 (26.0%)	29 (30.2%)	3 (37.5%)	42 (32.1%)	15 (21.7%)	19 (25.7%)	14 (23.7%)	24 (35.8%)
		Yes	30 (15.0%)	4 (13.8%)	5 (9.1%)	21 (18.1%)	13 (13.5%)	15 (15.6%)	2 (25.0%)	14 (10.7%)	16 (23.2%)	8 (10.8%)	15 (25.4%)	7 (10.4%)
		Absolutely yes	13 (6.5%)	2 (6.9%)	3 (5.5%)	8 (6.9%)	7 (7.3%)	6 (6.3%)	0	8 (6.1%)	5 (7.2%)	2 (2.7%)	4 (6.8%)	7 (10.4%)
		Symptoms present†	100 (50.0%)	15 (51.7%)	24 (43.6%)	61 (52.6%)	45 (46.9%)	50 (52.1%)	5 (62.5%)	64 (48.9%)	36 (52.2%)	29 (39.2%)	33 (55.9%)	38 (56.7%)
Joint/muscle pain	None at all	91 (45.5%)	11 (37.9%)	31 (56.4%)	49 (42.2%)	45 (46.9%)	42 (43.8%)	4 (50.0%)	58 (44.3%)	33 (47.8%)	29 (39.2%)	31 (52.5%)	31 (46.3%)	
		A little	68 (34.0%)	10 (34.5%)	14 (25.5%)	44 (37.9%)	33 (34.4%)	32 (33.3%)	3 (37.5%)	48 (36.6%)	20 (29.0%)	34 (45.9%)	17 (28.8%)	17 (25.4%)
		Yes	25 (12.5%)	3 (10.3%)	8 (14.5%)	14 (12.1%)	10 (10.4%)	14 (14.6%)	1 (12.5%)	12 (9.2%)	13 (18.8%)	9 (12.2%)	7 (11.9%)	9 (13.4%)
		Absolutely yes	16 (8.0%)	5 (17.2%)	2 (3.6%)	9 (7.8%)	8 (8.3%)	8 (8.3%)	0	13 (9.9%)	3 (4.3%)	2 (2.7%)	4 (6.8%)	10 (14.9%)
		Symptoms present†	109 (54.5%)	18 (62.1%)	24 (43.6%)	67 (57.8%)	51 (53.1%)	54 (56.3%)	4 (50.0%)	73 (55.7%)	36 (52.2%)	45 (60.8%)	28 (47.5%)	36 (53.7%)
	Fatigue/malaise	None at all	64 (32.0%)	10 (34.5%)	13 (23.6%)	41 (35.3%)	33 (34.4%)	29 (30.2%)	2 (25.0%)	40 (30.5%)	24 (34.8%)	30 (40.5%)	20 (33.9%)	14 (20.9%)
		A little	84 (42.0%)	11 (37.9%)	34 (61.8%)	39 (33.6%)	42 (43.8%)	41 (42.7%)	1 (12.5%)	53 (40.5%)	31 (44.9%)	30 (40.5%)	25 (42.4%)	29 (43.3%)
		Yes	33 (16.5%)	6 (20.7%)	3 (5.5%)	24 (20.7%)	13 (13.5%)	15 (15.6%)	5 (62.5%)	23 (17.6%)	10 (14.5%)	12 (16.2%)	10 (16.9%)	11 (16.4%)
		Absolutely yes	19 (9.5%)	2 (6.9%)	5 (9.1%)	12 (10.3%)	8 (8.3%)	11 (11.5%)	0	15 (11.5%)	4 (5.8%)	2 (2.7%)	4 (6.8%)	13 (19.4%)
		Symptoms present†	136 (68.0%)	19 (65.5%)	42 (76.4%)	75 (64.7%)	63 (65.6%)	67 (69.8%)	6 (75.0%)	91 (69.5%)	45 (65.2%)	44 (59.5%)	39 (66.1%)	53 (79.1%)
Neurological symptoms	Pain/numbness	None at all	53 (26.5%)	5 (17.2%)	18 (32.7%)	30 (25.9%)	24 (25.0%)	27 (28.1%)	2 (25.0%)	32 (24.4%)	21 (30.4%)	22 (29.7%)	18 (30.5%)	13 (19.4%)
		A little	52 (26.0%)	10 (34.5%)	19 (34.5%)	23 (19.8%)	27 (28.1%)	25 (26.0%)	0	36 (27.5%)	16 (23.2%)	22 (29.7%)	14 (23.7%)	16 (23.9%)
		Yes	41 (20.5%)	9 (31.0%)	6 (10.9%)	26 (22.4%)	17 (17.7%)	21 (21.9%)	3 (37.5%)	28 (21.4%)	13 (18.8%)	16 (21.6%)	11 (18.6%)	14 (20.9%)
		Absolutely yes	54 (27.0%)	5 (17.2%)	12 (21.8%)	37 (31.9%)	28 (29.2%)	23 (24.0%)	3 (37.5%)	35 (26.7%)	19 (27.5%)	14 (18.9%)	16 (27.1%)	24 (35.8%)
		Symptoms present†	147 (73.5%)	24 (82.8%)	37 (67.3%)	86 (74.1%)	72 (75.0%)	69 (71.9%)	6 (75.0%)	99 (75.6%)	48 (69.6%)	52 (70.3%)	41 (69.5%)	54 (80.6%)
	Motor function	None at all	115 (57.5%)	17 (58.6%)	35 (63.6%)	63 (54.3%)	53 (55.2%)	59 (61.5%)	3 (37.5%)	77 (58.8%)	38 (55.1%)	46 (62.2%)	34 (57.6%)	35 (52.2%)
		A little	50 (25.0%)	7 (24.1%)	16 (29.1%)	27 (23.3%)	27 (28.1%)	21 (21.9%)	2 (25.0%)	33 (25.2%)	17 (24.6%)	18 (24.3%)	10 (16.9%)	22 (32.8%)
		Yes	21 (10.5%)	4 (13.8%)	3 (5.5%)	14 (12.1%)	7 (7.3%)	12 (12.5%)	2 (25.0%)	10 (7.6%)	11 (15.9%)	7 (9.5%)	8 (13.6%)	6 (9.0%)
		Absolutely yes	14 (7.0%)	1 (3.4%)	1 (1.8%)	12 (10.3%)	9 (9.4%)	4 (4.2%)	1 (12.5%)	11 (8.4%)	3 (4.3%)	3 (4.1%)	7 (11.9%)	4 (6.0%)
		Symptoms present†	85 (42.5%)	12 (41.4%)	20 (36.4%)	53 (45.7%)	43 (44.8%)	37 (38.5%)	5 (62.5%)	54 (41.2%)	31 (44.9%)	28 (37.8%)	25 (42.4%)	32 (47.8%)
Skin symptoms	None at all	98 (49.0%)	13 (44.8%)	23 (41.8%)	62 (53.4%)	71 (54.2%)	42 (43.8%)	4 (50.0%)	71 (54.2%)	27 (39.1%)	45 (60.8%)	30 (50.8%)	23 (34.3%)	
	A little	60 (30.0%)	6 (20.7%)	19 (34.5%)	35 (30.2%)	30 (31.3%)	27 (28.1%)	3 (37.5%)	32 (24.4%)	28 (40.6%)	18 (24.3%)	17 (28.8%)	25 (37.3%)	
	Yes	29 (14.5%)	7 (24.1%)	8 (14.5%)	14 (12.1%)	7 (7.3%)	22 (22.9%)	0	18 (13.7%)	11 (15.9%)	9 (12.2%)	11 (18.6%)	9 (13.4%)	
	Absolutely yes	13 (6.5%)	3 (10.3%)	5 (9.1%)	5 (4.3%)	7 (7.3%)	5 (5.2%)	1 (12.5%)	10 (7.6%)	3 (4.3%)	2 (2.7%)	1 (1.7%)	10 (14.9%)	
	Symptoms present†	102 (51.0%)	16 (55.2%)	32 (58.2%)	54 (46.6%)	44 (45.8%)	54 (56.3%)	4 (50.0%)	60 (45.8%)	42 (60.9%)	29 (39.2%)	29 (49.2%)	44 (65.7%)	
Renal symptoms	None at all	182 (91.0%)	24 (82.8%)	48 (87.3%)	110 (94.8%)	89 (92.7%)	87 (90.6%)	6 (75.0%)	117 (89.3%)	65 (94.2%)	67 (90.5%)	55 (93.2%)	60 (89.6%)	
	A little	11 (5.5%)	4 (13.8%)	3 (5.5%)	4 (3.4%)	6 (6.3%)	4 (4.2%)	1 (12.5%)	8 (6.1%)	3 (4.3%)	5 (6.8%)	2 (3.4%)	4 (6.0%)	
	Yes	5 (2.5%)	1 (3.4%)	3 (5.5%)	1 (0.9%)	1 (1.0%)	3 (3.1%)	1 (12.5%)	4 (3.1%)	1 (1.4%)	2 (2.7%)	1 (1.7%)	2 (3.0%)	
	Absolutely yes	2 (1.0%)	0	1 (1.8%)	1 (0.9%)	0	2 (2.1%)	0	2 (1.5%)	0	0	1 (1.7%)	1 (1.5%)	
	Symptoms present†	18 (9.0%)	5 (17.2%)	7 (12.7%)	6 (5.2%)	7 (7.3%)	9 (9.4%)	2 (25.0%)	14 (10.7%)	4 (5.8%)	7 (9.5%)	4 (6.8%)	7 (10.4%)	
Gastrointestinal symptoms	None at all	162 (81.0%)	22 (75.9%)	47 (85.5%)	93 (80.2%)	80 (83.3%)	75 (78.1%)	7 (87.5%)	105 (80.2%)	57 (82.6%)	60 (81.1%)	46 (78.0%)	56 (83.6%)	
	A little	25 (12.5%)	6 (20.7%)	5 (9.1%)	14 (12.1%)	11 (11.5%)	13 (13.5%)	1 (12.5%)	15 (11.5%)	10 (14.5%)	11 (14.9%)	9 (15.3%)	5 (7.5%)	
	Yes	10 (5.0%)	1 (3.4%)	0	9 (7.8%)	5 (5.2%)	5 (5.2%)	0	8 (6.1%)	2 (2.9%)	3 (4.1%)	3 (5.1%)	4 (6.0%)	
	Absolutely yes	3 (1.5%)	0	3 (5.5%)	0	0	3 (3.1%)	0	3 (2.3%)	0	0	1 (1.7%)	2 (3.0%)	
	Symptoms present†	38 (19.0%)	7 (24.1%)	8 (14.5%)	23 (19.8%)	16 (16.7%)	21 (21.9%)	1 (12.5%)	26 (19.8%)	12 (17.4%)	14 (18.9%)	13 (22.0%)	11 (16.4%)	
Eye symptoms	None at all	137 (68.5%)	17 (58.6%)	39 (70.9%)	81 (69.8%)	69 (71.9%)	64 (66.7%)	4 (50.0%)	89 (67.9%)	48 (69.6%)	49 (66.2%)	42 (71.2%)	46 (68.7%)	
	A little	44 (22.0%)	9 (31.0%)	12 (21.8%)	23 (19.8%)	19 (19.8%)	22 (22.9%)	3 (37.5%)	26 (19.8%)	18 (26.1%)	21 (28.4%)	14 (23.7%)	9 (13.4%)	
	Yes	16 (8.0%)	3 (10.3%)	4 (7.3%)	9 (7.8%)	6 (6.3%)	9 (9.4%)	1 (12.5%)	14 (10.7%)	2 (2.9%)	3 (4.1%)	2 (3.4%)	11 (16.4%)	
	Absolutely yes	3 (1.5%)	0	0	3 (2.6%)	2 (2.1%)	1 (1.0%)	0	2 (1.5%)	1 (1.4%)	1 (1.4%)	1 (1.7%)	1 (1.5%)	
	Symptoms present†	63 (31.5%)	12 (41.4%)	16 (29.1%)	35 (30.2%)	27 (28.1%)	32 (33.3%)	4 (50.0%)	42 (32.1%)	21 (30.4%)	25 (33.8%)	17 (28.8%)	21 (31.3%)	
Ear symptoms	None at all	134 (67.0%)	16 (55.2%)	37 (67.3%)	81 (69.8%)	65 (67.7%)	65 (67.7%)	4 (50.0%)	90 (68.7%)	44 (63.8%)	51 (68.9%)	38 (64.4%)	45 (67.2%)	
	A little	42 (21.0%)	7 (24.1%)	16 (29.1%)	19 (16.4%)	20 (20.8%)	19 (19.8%)	3 (37.5%)	27 (20.6%)	15 (21.7%)	16 (21.6%)	13 (22.0%)	13 (19.4%)	
	Yes	16 (8.0%)	4 (13.8%)	2 (3.6%)	10 (8.6%)	6 (6.3%)	9 (9.4%)	1 (12.5%)	10 (7.6%)	6 (8.7%)	6 (8.1%)	6 (10.2%)	4 (6.0%)	
	Absolutely yes	8 (4.0%)	2 (6.9%)	0	6 (5.2%)	5 (5.2%)	3 (3.1%)	0	4 (3.1%)	4 (5.8%)	1 (1.4%)	2 (3.4%)	5 (7.5%)	
	Symptoms present†	66 (33.0%)	13 (44.8%)	18 (32.7%)	35 (30.2%)	31 (32.3%)	31 (32.3%)	4 (50.0%)	41 (31.3%)	25 (36.2%)	23 (31.1%)	21 (35.6%)	22 (32.8%)	
Nasal/paranasal symptoms	None at all	90 (45.0%)	11 (37.9%)	22 (40.0%)	57 (49.1%)	47 (49.0%)	41 (42.7%)	2 (25.0%)	57 (43.5%)	33 (47.8%)	37 (50.0%)	27 (45.8%)	26 (38.8%)	
	A little	48 (24.0%)	7 (24.1%)	20 (36.4%)	21 (18.1%)	29 (30.2%)	17 (17.7%)	2 (25.0%)	33 (25.2%)	15 (21.7%)	13 (17.6%)	14 (23.7%)	21 (31.3%)	
	Yes	34 (17.0%)	6 (20.7%)	8 (14.5%)	20 (17.2%)	9 (9.4%)	22 (22.9%)	3 (37.5%)	22 (16.8%)	12 (17.4%)	15 (20.3%)	10 (16.9%)	9 (13.4%)	
	Absolutely yes	28 (14.0%)	5 (17.2%)	5 (9.1%)	18 (15.5%)	11 (11.5%)	16 (16.7%)	1 (12.5%)	19 (14.5%)	9 (13.0%)	9 (12.2%)	8 (13.6%)	11 (16.4%)	
	Symptoms present†	110 (55.0%)	18 (62.1%)	33 (60.0%)	59 (50.9%)	49 (51.0%)	55 (57.3%)	6 (75.0%)	74 (56.5%)	36 (52.2%)	37 (50.0%)	32 (54.2%)	41 (61.2%)	
Asthmatic symptoms	None at all	88 (44.0%)	12 (41.4%)	20 (36.4%)	56 (48.3%)	54 (56.3%)	33 (34.4%)	1 (12.5%)	60 (45.8%)	28 (40.6%)	35 (47.3%)	26 (44.1%)	27 (40.3%)	
	A little	76 (38.0%)	11 (37.9%)	25 (45.5%)	40 (34.5%)	30 (31.3%)	42 (43.8%)	4 (50.0%)	47 (35.9%)	29 (42.0%)	30 (40.5%)	23 (39.0%)	23 (34.3%)	
	Yes	24 (12.0%)	3 (10.3%)	4 (7.3%)	17 (14.7%)	10 (10.4%)	12 (12.5%)	2 (25.0%)	15 (11.5%)	9 (13.0%)	8 (10.8%)	6 (10.2%)	10 (14.9%)	
	Absolutely yes	12 (6.0%)	3 (10.3%)	6 (10.9%)	3 (2.6%)	2 (2.1%)	9 (9.4%)	1 (12.5%)	9 (6.9%)	3 (4.3%)	1 (1.4%)	4 (6.8%)	7 (10.4%)	
	Symptoms present†	112 (56.0%)	17 (58.6%)	35 (63.6%)	60 (51.7%)	42 (43.8%)	63 (65.6%)	7 (87.5%)	71 (54.2%)	41 (59.4%)	39 (52.7%)	33 (55.9%)	40 (59.7%)	

Fig. S1 Patient-reported impressions of EGPA treatment at the time of the survey according to the use and dose of OGC

EGPA eosinophilic granulomatosis with polyangiitis, *OGC* oral glucocorticoids




Fig. S2 Improvements in EGPA treatments desired by patients according to the use and dose of OGC

EGPA eosinophilic granulomatosis with polyangiitis, *OGC* oral glucocorticoids






Fig. S3 Prevalence and severity of EGPA-related symptoms (a), number of symptoms (b), and most painful symptoms (c) experienced by the patients at the time of the worst relapse in the past year

EGPA eosinophilic granulomatosis with polyangiitis

a



b



C





Fig. S4 Prevalence and severity of EGPA-related symptoms among patients with an intractable disease subsidy among 55 patients not using an anti-IL-5/R α biologic (a) and 116 patients using an anti-IL-5/R α biologic (b)

EGPA eosinophilic granulomatosis with polyangiitis, IL interleukin, R α receptor α

a



b




Fig. S5 Proportions of patients with EGPA-related symptoms in the past month according to the use and dose of OGC

EGPA eosinophilic granulomatosis with polyangiitis, OGC oral glucocorticoids

